Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy

Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large pharmaceutical companies Pfizer, Sanofi-Aventis, Eli Lilly & Company and Merck & Co all have substantial investment in the RNA/DNA therapy products market. With Merck & Co in particularly showing its faith in the future potential of this market by taking the gamble of acquiring the specialist RNAi company Sirna, towards the end of 2006.

This interest reflects the advances being made in this sector and implies that it is eventually on the verge of success. The investment of these larger companies makes that success both more likely to occur and more likely to occur quickly. Are you missing out? Have you positioned your company correctly to benefit from these opportunities? The vast potential of RNA/DNA therapies to treat the cause of disease across many therapeutic areas is set to be realized. Be part of that now.

This brand new high-level management report focuses on the commercial and strategic opportunities within the human genome project. It examines the companies utilizing novel molecular biological techniques to try to exploit this knowledge to produce RNA/DNA products. The genetic characterisation of many viruses is also leading to DNA and RNA products being used to treat infectious disease, a therapeutic area for which traditional drug development is difficult, as with the recent announcement regarding AIDS research.

Visiongain has identified 68 companies actively involved in this field, 35 of these companies are primarily focused on the development of RNA/DNA therapy products and 33 companies are involved in collaborations. This represents a substantial investment in the future of the RNA/DNA therapy products market and over the forecast period visiongain believes this investment will begin to pay off. There are 2 RNA/DNA therapy products due to submit licence applications in 2007, with a further 67 products in clinical trials and a further 45 products in pre-clinical development. Of these products visiongain has identified 14 that it believes have the greatest potential both to be launched before 2012 and to make a contribution to this market. This would result in a substantial increase in the RNA/DNA therapy product market over the forecast period and imply that this sector is eventually achieving some of its anticipated potential.

• Receive an in-depth, accurate and up to date understanding of the of the RNA/DNA therapy products market and a forecast of the markets
• Utilise our comprehensive review of the technologies being developed for RNA/DNA therapy products
• Align yourself with the top companies involved in RNA/DNA therapy product development are
• Benefit from the companies already in collaborations and understand how you can be part of it
• Choosing the right partner can be difficult - this report will tell you which companies are likely to be open to collaborations or licensing agreements.
• Have an insight as to which products are likely to be launched over the next 10 years
• Which sector of the RNA/DNA therapy market are you most likely to succeed in? This report tells you
• Achieve first move advantage on which therapeutic sectors are likely to benefit from RNA/DNA therapy products
• Understand why this market is beginning to become successful - now
• Be prepared for the larger pharmaceutical companies moves within this sector
• Play to your strengths and opportunities but avoid your weaknesses and threats of the RNA/DNA therapy products market

There are many companies using established and novel molecular biological techniques to try to produce successful RNA/DNA products for a variety of indications. However, even with substantial investment, the RNA/DNA therapy products market is still in its infancy, only three products have obtained a licence and only Macugen, for wet AMD, is actively available on the worldwide markets. RNA/DNA therapy products have faced problems, principally due to immunogenicity and in proving effective enough, primarily due to inefficient delivery systems.

• The leading RNA/DNA therapy companies and products
• Clear analysis of the market divides into aptamer, antisense, DNA therapy products and RNA therapy products, sectors
• In-depth analysis and profiles of the leading companies, together with their leading and developmental products.
• visiongain' s top 5 ranked companies in each sector and identified products with the potential to be launched within the forecast period.

In the short term the leading potential therapeutic area for RNA/DNA therapy products is ocular disease. Macugen, an aptamer for the treatment of wet AMD, is the only RNA/DNA product currently available worldwide. Visiongain predicts that Macugen will lead the RNA/DNA therapy products market between 2007 to 2012, generating in the region of $1.7bn in cumulative sales over this period. However, it is the cardiovascular sector, with 5 products predicted to launch before 2012, where visiongain anticipates RNA/DNA therapy products will ultimately have the greatest impact.

DNA therapy products is the sector that has the greatest investment, with the most specialist companies and the greatest number of products predicted to launch prior to 2012. However, antisense is the sector with the most collaborating companies and it also has the product Genasense, which has filed for an EU and US license, although it is encountering problems in obtaining these licenses and its future is by no means certain.

RNAi technology undoubtedly has huge potential for developing products in many therapeutic areas. The investment in novel, often nanoparticle, delivery systems for RNAi products may ensure that this potential is ultimately realised. If solutions for efficient delivery of RNAi can be solved early on in RNAi development the RNA/DNA therapy market may see a future expansion due to successful RNAi therapies. RNAi has the potential to emerge as a dominant section of the RNA/DNA therapy products market, but only time will tell if it can ultimately fulfil this potential. Over the forecast period 2007-2012 RNA therapy products are not likely to generate substantial sales.

• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using hard drive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables